CR20220367A - Célula cho que expresa heterodímeros il-15 - Google Patents

Célula cho que expresa heterodímeros il-15

Info

Publication number
CR20220367A
CR20220367A CR20220367A CR20220367A CR20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A
Authority
CR
Costa Rica
Prior art keywords
cho cell
heterodimers
cell expressing
heterodimer
producing
Prior art date
Application number
CR20220367A
Other languages
English (en)
Inventor
Justyna Jozefczuk
Urs Ulrich Lohrig
Richard Gabriel
Thomas Jostock
Alexandre Aurélien Pons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20220367A publication Critical patent/CR20220367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL–15/IL–15Ra producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
CR20220367A 2020-02-05 2021-01-29 Célula cho que expresa heterodímeros il-15 CR20220367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
CR20220367A true CR20220367A (es) 2022-08-30

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220367A CR20220367A (es) 2020-02-05 2021-01-29 Célula cho que expresa heterodímeros il-15

Country Status (21)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
TW (1) TW202142558A (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
US20230398185A1 (en) 2020-10-26 2023-12-14 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
CN102796743B (zh) * 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CA2727953C (en) 2008-08-22 2017-05-16 Magna Seating Inc. Disc recliner with reduced backlash
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103370339B (zh) 2010-09-21 2017-12-26 阿尔托生物科学有限公司 多聚体il‑15可溶性融合分子与其制造与使用方法
CA2888896A1 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
PT3137595T (pt) 2014-04-29 2019-06-19 Novartis Ag Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse
CA2970385C (en) * 2014-12-19 2023-04-04 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
AU2017305335B2 (en) * 2016-08-01 2021-11-18 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
JP2020505350A (ja) * 2017-01-20 2020-02-20 ノバルティス アーゲー 癌の治療のための組合せ療法
AU2019213843A1 (en) * 2018-02-02 2020-08-20 Aduro Biotech Inc. Combination of STING agonist and IL-15/IL15-Ra for the treatment of cancer
CN111819203A (zh) * 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体

Also Published As

Publication number Publication date
CN115023436A (zh) 2022-09-06
ECSP22060286A (es) 2022-09-30
CO2022010860A2 (es) 2022-08-19
JP2023145622A (ja) 2023-10-11
MX2022009611A (es) 2022-11-07
AR121261A1 (es) 2022-05-04
EP4100425A1 (en) 2022-12-14
WO2021156720A1 (en) 2021-08-12
CA3168469A1 (en) 2021-08-12
US20210244821A1 (en) 2021-08-12
KR20220137651A (ko) 2022-10-12
JOP20220174A1 (ar) 2023-01-30
IL295278A (en) 2022-10-01
JP2022522566A (ja) 2022-04-20
UY39062A (es) 2021-09-30
CL2023002447A1 (es) 2024-03-15
BR112022014493A2 (pt) 2022-09-20
PE20221509A1 (es) 2022-10-04
AU2021215893A1 (en) 2022-08-25
TW202142558A (zh) 2021-11-16
DOP2022000156A (es) 2022-10-16
CL2022002094A1 (es) 2023-03-10

Similar Documents

Publication Publication Date Title
CR20220367A (es) Célula cho que expresa heterodímeros il-15
GB2556847A (en) Dynamic capacity ranges for workforce routing
PH12018500971A1 (en) Method and device for application information risk management
MX2018002293A (es) Sistemas y métodos para las llamadas variantes de alta precisión.
GB2500332A (en) System and method for performing downhole stimulation operations
DE60314176D1 (de) Verfahren und vorrichtung zur bereitstellung von nachrichtenorientierten sprachkommunikationen zwischen mehreren partnern
MX2021004484A (es) Compuesto de capas para ser usado como piel de imitacion.
MX2011011729A (es) Anticuerpo anti il-17f y metodos de uso de los mismos.
PH12017500055B1 (en) Plant inoculation method
SG10201803837VA (en) Blockchain system and data managing method using blockchain
EA201100639A1 (ru) Угольный блок-фильтр
MX2013005978A (es) Gel reticulado de poliamina y método de uso.
MX2020010204A (es) Anticuerpos anti-trem-1 y usos de los mismos.
MX2015011117A (es) Metodo para producir un material con ultra elevada resistencia y con alta elongacion.
AU201817859S (en) Walker frame
MX2022002269A (es) Plantas transformadas y metodos para elaborar y utilizar las mismas.
MX2021001223A (es) Fabricacion aditiva de componentes estructurales con base en carburo de silicio con particulas de diamante incrustadas.
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
PH12018550124A1 (en) System and method for treating sleep apnea while straightening teeth
WO2019152271A3 (en) Metal orthodontic retainer or dental flipper
SA517390305B1 (ar) أنظمة وطرق متعلقة بإنتاج الأوليفين
MX2021010445A (es) Metodos y aparatos para producir superficies rugosas.
MX2018010664A (es) Radiomensajeria de un nodo de cliente en un sistema de comunicaciones de grupo.
WO2016201143A8 (en) Constructing additive trees monotonic in selected sets of variables
MX2020011666A (es) Procedimiento y dispositivo de clasificacion para clasificar objetos en forma de plancha, preferentemente recortes de placa de vidrio, procedimiento y dispositivo para fabricar recortes de placa de vidrio con un dispositivo de clasificacion de este tipo.